GERMANTOWN, Md., Jan. 27,
2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq:
PGEN) announced today the closing of its previously announced
underwritten public offering of common stock. Precigen sold
42,857,143 shares of its common stock at a public offering price of
$1.75 per share. Gross proceeds to
Precigen from the offering were approximately $75.0 million before deducting the underwriting
discount and other offering expenses payable by Precigen.
J.P. Morgan Securities LLC acted as the lead book-running
manager for the offering. Cantor Fitzgerald & Co. also acted as
book-running manager. JMP Securities, a Citizens Company, acted as
lead manager and H.C. Wainwright & Co., LLC acted as co-manager
for the offering.
The public offering was made pursuant to a shelf registration
statement on Form S-3 that was previously filed with the Securities
and Exchange Commission (SEC) and became effective on July 2, 2020. A final prospectus supplement
relating to and describing the terms of the offering has been filed
with the SEC and is available on the website of the SEC
at www.sec.gov. Copies of the final prospectus supplement
and accompanying base prospectus relating to the offering may also
be obtained from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone:
1-866-803-9204, or by emailing at
prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Precigen
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical
stage biopharmaceutical company advancing the next generation of
gene and cell therapies using precision technology to target the
most urgent and intractable diseases in our core therapeutic areas
of immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's technologies are designed to enable us to find
innovative solutions for affordable biotherapeutics in a controlled
manner. Precigen operates as an innovation engine progressing a
preclinical and clinical pipeline of well-differentiated unique
therapies toward clinical proof-of-concept and
commercialization.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release are
forward-looking statements. These forward-looking statements are
based upon Precigen's current expectations and projections about
future events. Various factors may cause differences between
Precigen's expectations and actual results. These risks and
uncertainties include, without limitation, risks and uncertainties
related to market conditions. For further information on potential
risks and uncertainties, and other important factors, any of which
could cause Precigen's actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in Precigen's most recent Annual Report on
Form 10-K and subsequent reports filed with the Securities and
Exchange Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-announces-closing-of-public-offering-of-common-stock-301732560.html
SOURCE Precigen, Inc.